Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

The film gives the main points. The full list below is copied from the registry; the study team makes the final decision.

• Age12 Years to no maximum
• SexAll
• Healthy volunteersNo

You may be able to join if

• The main inclusion criteria include but are not limited to the following:
• Male and female participants at least 12 years of age (at least 18 years of age for Cohort B1)
• Diagnosis of one of the following: Advanced/metastatic pheochromocytoma/paraganglioma (PPGL), pancreatic neuroendocrine tumors (pNET), von Hippel-Lindau (VHL) disease associated localized tumors, or advanced wild-type gastrointestinal stromal tumor (wt GIST) or advanced solid tumors with Hypoxia Inducible Factor- 2 alpha subunit (HIF-2α) related genetic alterations
• Cohort B1: VHL Disease-associated tumors:
• Have a diagnosis of VHL disease as determined by a germline test locally and/or clinical diagnosis
• Must be ≥18 years of age
• Has a life expectancy of at least 3 months
• The main exclusion criteria include but are not limited to the following:
• Unable to swallow orally administered medication or has a disorder that might affect the absorption of belzutifan
• History of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years
• Any of the following: A pulse oximeter reading <92% at rest, or requires intermittent supplemental oxygen, or requires chronic supplemental oxygen
• Clinically significant cardiac disease, including unstable angina, acute myocardial infarction, or arterial bypass (CABG) or Percutaneous transluminal coronary angioplasty (PTCA) ≤6 months from study entry, or New York Heart Association Class III or IV congestive heart failure
• Received prior treatment (except somatostatin analogs) with chemotherapy, targeted therapy, biologics, or other investigational therapy within the past 4 weeks of first dose of study intervention

This is how the treatment is meant to work. Whether it helps, and how safe it is, is what this trial is testing.

belzutifan. An orally active, small molecule inhibitor of hypoxia inducible factor (HIF)-2alpha (HIF-2a), with potential antineoplastic activity. Upon oral administration, belzutifan binds to and blocks the function of HIF-2alpha, thereby preventing HIF-2alpha heterodimerization and its subsequent binding to DNA. This results in decreased transcription and expression of HIF-2alpha downstream target genes, many of which regulate hypoxic signaling. This inhibits cell growth and survival of HIF-2alpha-expressing tumor cells. HIF-2alpha, the alpha subunit for the heterodimeric transcription factor HIF-2, is overexpressed in many cancers and promotes tumorigenesis. NCI Drug Dictionary

Treatments listed in the registry

• Belzutifan (Drug): Belzutifan, 120 mg, oral, once daily (QD) until progressive disease or discontinuation.

Na · Single Group · masking: None

Main goals

• Objective Response Rate (ORR) as Assessed by Blinded Independent Central Review (BICR) (Up to approximately 5.5 years)

Other goals

• Duration of Response (DOR) as Assessed by BICR
• Time to Response (TTR) as Assessed by BICR
• Disease Control Rate (DCR) as Assessed by BICR
• Progressive Free Survival (PFS) as Assessed by BICR
• Overall Survival (OS)
• Number of Participants Who Experience an Adverse Event (AE)
• Number of Participants Who Discontinue Study Treatment Due to an AE
• Time to Surgery (TTS)

Planned enrollment: 355 (estimated).

• Cedars-Sinai Medical Center ( Site 0110), Los Angeles, California
• Northwestern University - Robert H. Lurie Comprehensive Cancer Center ( Site 0130), Chicago, Illinois
• Northwestern Medicine Cancer Center - Warrenville ( Site 0134), Warrenville, Illinois
• University of Iowa ( Site 0104), Iowa City, Iowa
• Johns Hopkins Hospital-Sidney Kimmel Comprehensive Cancer Center - Developmental Therapeutics ( Site 0108), Baltimore, Maryland
• National Institutes of Health ( Site 0125), Bethesda, Maryland
• Massachusetts General Hospital ( Site 0111), Boston, Massachusetts
• University of Michigan ( Site 0126), Ann Arbor, Michigan
• Vanderbilt University Medical Center ( Site 0107), Nashville, Tennessee
• University of Texas MD Anderson Cancer Center ( Site 0112), Houston, Texas

37 recruiting sites outside the US. Site status as of Oct 30, 2026. Check the live record before contacting a site.

These papers are listed in the registry record. Unless a paper is marked as about this trial, it is background research on the treatment or disease, not results from this study.

• Publication about this trial (to be verified before citing)Jimenez C, Andreassen M, Durand A, Moog S, Hendifar A, Welin S, Spada F, Sharma R, Wolin E, Ruether J, Garcia-Carbonero R, Fassnacht M, Capdevila J, Del Rivero J, Iliopoulos O, Huillard O, Jang R, Mai K, Artamonova E, Hallqvist A, Else T, Odeleye-Ajakaye A, Gozman A, Naik GS, Berruti A; LITESPARK-015 Investigators. Belzutifan for Advanced Pheochromocytoma or Paraganglioma. N Engl J Med. 2025 Nov 20;393(20):2012-2022. doi: 10.1056/NEJMoa2504964. Epub 2025 Oct 18.

• ClinicalTrials.gov NCT04924075
• NCI Drug Dictionary: C135627

Registry record reviewed as fetched Oct 30, 2026, last updated by the sponsor Oct 20, 2026. Public record; not medical advice.